1,420
Trials as lead sponsor
Most active programmes
The drugs appearing most often across Novo Nordisk's recently active trials. Comparator arms are excluded.
- Semaglutide22 trials
- Cagrilintide10 trials
- NNC0487-01119 trials
- Insulin icodec6 trials
- Concizumab4 trials
- Etavopivat4 trials
Upcoming readouts
Next primary completion dates among Novo Nordisk's active phase 2 and phase 3 trials. Dates are registry estimates and move often, which is exactly what the tracker watches.
- May 2027RENEW 4: A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in Peo…Phase 3
- Aug 2027HIBISCUS 3: A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Veloci…Phase 2
- Aug 2027Hibiscus 2: A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseasePhase 3
- Sept 2027A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sug…Phase 2
- Oct 2027A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in …Phase 2
- Nov 20278212-Preserved: A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function…Phase 2
Top therapeutic areas
Conditions studied most often across Novo Nordisk's recently active trials.
- Obesity41 trials
- Overweight26 trials
- Diabetes Mellitus, Type 214 trials
- Type 2 Diabetes7 trials
- Heart Failure5 trials
- Diabetes Mellitus, Type 15 trials
Novo Nordisk pipeline by phase
The main study drugs across 117 active trials Novo Nordisk leads on ClinicalTrials.gov. Each drug sits in the highest phase among its currently active trials, which can be lower than a phase it has already completed.
Phase 315 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| NNC0487-0111 | 13 | 10 | Nov 2027 est. | NCT07571109 · NCT07571005 · NCT07567001 |
| Cagrilintide | 11 | 6 | Apr 2027 est. | NCT07745504 · NCT07253285 · NCT07220759 |
| Zenagamtide | 4 | 1 | Jun 2028 est. | NCT07797335 · NCT07720271 · NCT07668414 |
| Concizumab | 3 | — | — | NCT05135559 · NCT04083781 · NCT04082429 |
| Etavopivat | 3 | 3 | Aug 2027 est. | NCT06612268 · NCT06198712 · NCT05953584 |
| Somapacitan | 3 | — | — | NCT05723835 · NCT05330325 · NCT03878446 |
| Ziltivekimab | 3 | 1 | Oct 2026 est. | NCT07301034 · NCT06200207 · NCT06118281 |
| CagriSema | 2 | 1 | Jun 2027 est. | NCT07817251 · NCT07564414 |
| CagriSema (Cagrilintide B and Semaglutide I) | 2 | 1 | Mar 2027 est. | NCT07282613 · NCT07011667 |
| DCR-PHXC | 2 | 1 | Apr 2030 est. | NCT04042402 · NCT04580420 |
| Liraglutide | 2 | 1 | Dec 2026 est. | NCT04775082 · NCT07225816 |
| NNC6019-0001 | 2 | 1 | Feb 2028 est. | NCT07207811 · NCT06260709 |
| Etavopivat A | 1 | 1 | Dec 2030 est. | NCT06609226 |
| Etavopivat Tablets Low dose | 1 | — | — | NCT04624659 |
| Mim8 | 1 | — | Jun 2028 est. | NCT05685238 |
Phase 24 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| NNC0662-0419 | 4 | 2 | Dec 2026 est. | NCT07639021 · NCT07415954 · NCT07184632 |
| UBT251 | 4 | 4 | Jan 2027 est. | NCT07668388 · NCT07395687 · NCT07710768 |
| CDR132L | 2 | 2 | May 2027 est. | NCT06979375 · NCT06979362 |
| NNC0519-0130 | 1 | 1 | — | NCT06717698 |
Phase 124 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| NNC0537-1482 | 2 | 1 | Jan 2027 est. | NCT07808788 · NCT07218627 |
| Cagrilintide D | 1 | 1 | May 2027 est. | NCT07597018 |
| CagriSema (Cagrilintide B + semaglutide I) | 1 | — | Oct 2027 est. | NCT07184086 |
| CDR132L (i.v.) | 1 | 1 | Dec 2026 est. | NCT07656454 |
| Coramitug | 1 | 1 | May 2027 est. | NCT07448623 |
| DCR-PDL1 | 1 | 1 | — | NCT06504368 |
| Glucose-dependent Insulinotropic Polypeptide (GIP) | 1 | 1 | Jan 2027 est. | NCT07411560 |
| INV-347 | 1 | 1 | Sept 2027 est. | NCT07153172 |
| NNC0113-5840 | 1 | 1 | Jan 2027 est. | NCT07566390 |
| NNC0194-0499 | 1 | — | — | NCT07087795 |
| NNC0442-0344 A | 1 | 1 | Feb 2027 est. | NCT07220564 |
| NNC0497-0040 | 1 | 1 | Feb 2028 est. | NCT07578584 |
| NNC0581-0001 | 1 | 1 | Oct 2027 est. | NCT06891365 |
| NNC0638-0355 | 1 | — | Oct 2027 est. | NCT06577766 |
| NNC0705-0002 | 1 | — | Aug 2027 est. | NCT07797855 |
| NNC0721-8060 | 1 | 1 | Sept 2027 est. | NCT07767175 |
| NNC1679-0001 | 1 | 1 | Jun 2028 est. | NCT07570992 |
| NNC4004-0002 | 1 | 1 | — | NCT06859073 |
| NNC4005-001 | 1 | 1 | May 2027 est. | NCT07214870 |
| NNC6022-0004 | 1 | 1 | Aug 2027 est. | NCT07693868 |
| NNC6989-0001 | 1 | 1 | Jan 2027 est. | NCT07437079 |
| NNC9733-0001 | 1 | 1 | Mar 2028 est. | NCT07270731 |
| Syringe Pump | 1 | 1 | Dec 2026 est. | NCT07769489 |
| Zenagamtide injection | 1 | — | Jun 2028 est. | NCT07815067 |
Phase 43 drugs
| Drug | Trials | Recruiting | Next readout | Sample trials |
|---|---|---|---|---|
| Semaglutide | 11 | 1 | Oct 2026 est. | NCT06571383 · NCT07770841 · NCT05726227 |
| Insulin icodec | 4 | 1 | Jan 2027 est. | NCT07112339 · NCT07076199 · NCT07658417 |
| Eptacog alfa (NovoSeven) | 1 | 1 | Aug 2027 est. | NCT07157423 |
Derived from 117 active trials Novo Nordisk leads; 116 name an intervention, folding into 46 phased drugs. 4 interventions carry no registry phase (observational studies, tests and devices) and are not shown. This is ComplyRx's reading of the registry, not Novo Nordisk's own pipeline disclosure.
Novo Nordisk trials
The 50 most significant of Novo Nordisk's recently active trials, soonest estimated readout first.
Select any row for the full record; the change timeline unlocks with tracking.
| Trial | Phase | Stability | Status | Enrollment | Est. readout |
|---|---|---|---|---|---|
| Korean Real-world Study on MASLD/MASH Outcomes.NCT07739901No treatment is given | — | Not yet scored | OngoingActive, not recruiting | 10,000 est. | 30 Sept 2026 |
| ATHENAA Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and InflammationNCT06200207Ziltivekimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 680 est. | 1 Oct 2026 |
| SCALA-TK-CMA Retrospective Real-World Cohort StudyNCT07781371 | — | Locked · track to reveal | OngoingNot yet recruiting | 100,000 est. | 2 Nov 2026 |
| RISEStudy to Assess Tolerability of Injecting Larger Volumes (2-5 mL) Subcutaneously at Different Rates: Participant Experience and AcceptanceNCT07769489Syringe Pump | Phase 1 | Locked · track to reveal | OngoingRecruiting | 100 est. | 9 Dec 2026 |
| Examination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected)NCT07225816Liraglutide | Phase 1 | Locked · track to reveal | OngoingRecruiting | 71 est. | 13 Dec 2026 |
| Database Linkage Study to Evaluate the Risk of Medullary Thyroid CarcinomaNCT07713901 | — | Not yet scored | OngoingEnrolling by invitation | 93,600,000 est. | 31 Dec 2026 |
| A Research Study on the Effects of NNC0537-1482 in Participants With Heart FailureNCT07218627NNC0537-1482 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 36 est. | 15 Jan 2027 |
| A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood SugarNCT07160816Insulin icodec | — | Not yet scored | OngoingActive, not recruiting | 245 est. | 20 Jan 2027 |
| A Study to See How Safe a New Medicine (NNC6989-0001) is in Healthy People Living With Overweight or ObesityNCT07437079NNC6989-0001 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 132 est. | 21 Jan 2027 |
| ONWARDS 11A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 DiabetesNCT07076199Insulin icodec | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 877 est. | 25 Jan 2027 |
| ARTEMISARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart AttackNCT06118281Ziltivekimab | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 10,000 est. | 29 Jan 2027 |
| A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or ObesityNCT07566390NNC0113-5840 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 48 est. | 31 Jan 2027 |
| VOYAGER2A Research Study Looking at How Different Doses of Study Medicine (Inno8) Work in the Body of People With Haemophilia ANCT07220564NNC0442-0344 A | Phase 1 | Locked · track to reveal | OngoingRecruiting | 30 est. | 5 Feb 2027 |
| A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-termNCT07011667CagriSema (Cagrilintide B and Semaglutide I) | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 609 est. | 1 Mar 2027 |
| CRISTALSEAA Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) ParticipantsNCT07532863 | — | Not yet scored | OngoingRecruiting | 400 est. | 27 Mar 2027 |
| A Research Study on How UBT251 Affects Levels of Midazolam, Caffeine and Warfarin in the Blood of Participants With Excess Body WeightNCT07710768UBT251 | Phase 1 | Not yet scored | OngoingRecruiting | 44 est. | 7 Apr 2027 |
| A Research Study Looking Into How UBT251 Works With Birth Control Tablets and Emptying of the Stomach in Women With Excess Body Weight Not Able to Become PregnantNCT07710729UBT251 | Phase 1 | Not yet scored | OngoingRecruiting | 40 est. | 27 Apr 2027 |
| RENEW 1Weight Loss in People Living With Overweight or Obesity Following Treatment With CagrilintideNCT07220642Cagrilintide | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 300 est. | 11 May 2027 |
| RENEW 2Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With CagrilintideNCT07220759Cagrilintide | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 330 est. | 12 May 2027 |
| RENEW 4A Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body WeightNCT07745504Cagrilintide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 285 est. | 18 May 2027 |
| Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to CagrisemaNCT07817251CagriSema | Phase 3 | Locked · track to reveal | OngoingNot yet recruiting | 210 est. | 9 Jun 2027 |
| A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With ObesityNCT07639021NNC0662-0419 | Phase 2 | Locked · track to reveal | OngoingActive, not recruiting | 233 est. | 14 Jun 2027 |
| A Research Study Looking Into How a Single Dose of the Medicine NNC0537-1482 Moves Through the Body of Participants With Normal or Reduced Kidney FunctionNCT07808788NNC0537-1482 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 54 est. | 6 Jul 2027 |
| General Use-results Surveillance With Awiqli in Patients With Diabetes MellitusNCT06807190Insulin Icodec | — | Not yet scored | OngoingRecruiting | 630 est. | 31 Jul 2027 |
| A Study to See How Safe a New Medicine (NNC0705-0002) is in Healthy PeopleNCT07797855NNC0705-0002 | Phase 1 | Not yet scored | OngoingNot yet recruiting | 112 est. | 1 Aug 2027 |
| A Study to See How Safe a New Medicine (NNC6022-0004) is in Healthy People and People Living With ObesityNCT07693868NNC6022-0004 | Phase 1 | Not yet scored | OngoingRecruiting | 128 est. | 3 Aug 2027 |
| A Study to Evaluate the Safety of Exposure to Wegovy During PregnancyNCT05503927 | — | Locked · track to reveal | OngoingEnrolling by invitation | 2,701 est. | 15 Aug 2027 |
| HIBISCUS 3A Phase 2 Open-label Study to Evaluate the Activity of Etavopivat on Transcranial Doppler Velocities in Pediatric Patients With Sickle Cell Disease Who Are at Increased Risk for Primary StrokeNCT05953584Etavopivat | Phase 2 | Locked · track to reveal | OngoingRecruiting | 27 est. | 20 Aug 2027 |
| A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in IndiaNCT07157423Eptacog alfa (NovoSeven) | Phase 4 | Locked · track to reveal | OngoingRecruiting | 64 est. | 26 Aug 2027 |
| Hibiscus 2A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell DiseaseNCT06612268Etavopivat | Phase 3 | Locked · track to reveal | OngoingRecruiting | 408 est. | 27 Aug 2027 |
| REDEFINE 3REDEFINE 3: A Research Study to See the Effects of CagriSema in People Living With Diseases in the Heart and Blood VesselsNCT05669755Cagrilintide | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 7,101 est. | 1 Sept 2027 |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 DiabetesNCT07415954NNC0662-0419 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 270 est. | 3 Sept 2027 |
| A First-in-human Research Study on How NNC0721-8060 Works in People Living With Overweight or ObesityNCT07767175NNC0721-8060 | Phase 1 | Locked · track to reveal | OngoingRecruiting | 142 est. | 23 Sept 2027 |
| A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 DiabetesNCT07668388UBT251 | Phase 2 | Locked · track to reveal | OngoingRecruiting | 300 est. | 4 Oct 2027 |
| A Research Study on How NNC0638-0355, a New Medicine, Works in People Living With Overweight or ObesityNCT06577766NNC0638-0355 | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 63 est. | 11 Oct 2027 |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to DietNCT07184086CagriSema (Cagrilintide B + semaglutide I) | Phase 1 | Locked · track to reveal | OngoingActive, not recruiting | 80 est. | 12 Oct 2027 |
| FOCUSA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 DiabetesNCT03811561Semaglutide | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 1,500 est. | 7 Nov 2027 |
| 8212-PreservedA Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular HypertrophyNCT06979362CDR132L | Phase 2 | Locked · track to reveal | OngoingRecruiting | 200 est. | 16 Nov 2027 |
| ICOSWITCH REALResearch Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin IcodecNCT07658417Insulin icodec | — | Locked · track to reveal | OngoingEnrolling by invitation | 216 est. | 1 Dec 2027 |
| OASIS 5Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body WeightNCT07770841Semaglutide | Phase 3 | Locked · track to reveal | OngoingRecruiting | 450 est. | 22 Feb 2028 |
| A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose WeightNCT07564414Cagrisema | Phase 3 | Locked · track to reveal | OngoingRecruiting | 2,500 est. | 23 Feb 2028 |
| HIBISCUS KIDSA Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients With Sickle Cell DiseaseNCT06198712Etavopivat | Phase 2 | Locked · track to reveal | OngoingRecruiting | 95 est. | 23 Feb 2028 |
| A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 DiabetesNCT07112339Insulin icodec | Phase 4 | Locked · track to reveal | OngoingRecruiting | 586 est. | 23 Mar 2028 |
| RAMBOThe Role of the Amylin Analogue Cagrilintide in Bone MetabolismNCT07010432Cagrilintide | Phase 1 | Locked · track to reveal | OngoingRecruiting | 144 est. | 3 May 2028 |
| AMAZE 12AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight LossNCT07503210NNC0487-0111 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 606 est. | 6 Jun 2028 |
| A Research Study Looking at the Effect of Timing of Meal After Dosing and Water Volume at Dosing on How the Medicine Zenagamtide is Taken up by the Body of Participants With Overweight or ObesityNCT07815067Zenagamtide injection | Phase 1 | Not yet scored | OngoingNot yet recruiting | 320 est. | 12 Jun 2028 |
| AMAZE 4AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571109NNC0487-0111 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 300 est. | 26 Jun 2028 |
| AMAZE 9AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose WeightNCT07720271zenagamtide | Phase 3 | Not yet scored | OngoingNot yet recruiting | 950 est. | 27 Jun 2028 |
| FRONTIER4A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia ANCT05685238Mim8 | Phase 3 | Locked · track to reveal | OngoingActive, not recruiting | 451 est. | 30 Jun 2028 |
| AMAZE 3AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep ApnoeaNCT07571005NNC0487-0111 | Phase 3 | Locked · track to reveal | OngoingRecruiting | 300 est. | 12 Jul 2028 |